25 September 2025 - Vertex announced today that the FDA has granted breakthrough therapy designation to povetacicept for the treatment of IgA nephropathy.

Povetacicept is an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines with best in class potential in IgA nephropathy and other B cell-driven diseases.

Read Vertex Pharmaceuticals press release